Targeting KRAS mutations with HLA class II-restricted TCRs for the treatment of solid tumors

T-cell receptor (TCR) redirected T cells are considered as the next generation of care for the treatment of numerous solid tumors. KRAS mutations are driver neoantigens that are expressed in over 25% of all cancers and are thus regarded as ideal targets for Adoptive Cell Therapy (ACT). We have isola...

Full description

Bibliographic Details
Published in:OncoImmunology
Main Authors: Pierre Dillard, Nicholas Casey, Sylvie Pollmann, Patrik Vernhoff, Gustav Gaudernack, Gunnar Kvalheim, Sébastien Wälchli, Else Marit Inderberg
Format: Article
Language:English
Published: Taylor & Francis Group 2021-01-01
Subjects:
immunotherapy
adoptive cell therapy
tcr
kras
Online Access:http://dx.doi.org/10.1080/2162402X.2021.1936757

Similar Items

Similar Items